Verify Before Publishing

Alli is a trademarked drug brand owned by GSK, the only FDA approved over the counter weight loss drug. Confirm program authorization and OTC drug advertising rules before publishing. Between 1999 and 2008 the FDA reviewed 32 reports of serious liver injury linked to orlistat, the ingredient in Alli. The FDA completed its safety review in 2010, did not confirm a cause and effect link, and Alli was never recalled. See the Compliance History section below.

Affiliate Program

Alli Affiliate Program: History & Current Options

Trademarked OTC drug with a documented FDA safety review. Verify program authorization and review Compliance History before publishing.

This guide reviews alli as an affiliate publishing topic, explains which current directory routes are relevant, and separates historical offer information from approved campaign terms.

Program status reviewed October 15, 2026Publisher guide

Current program status

This page covers an older Alli affiliate-program topic. A current campaign under that exact name has not been verified in the current public product directory. Do not use an earlier launch announcement, payout, trial or geographic claim as current offer terms. A private medical weight-loss category is a separate opportunity, not proof of an authorized Alli affiliate campaign. For a separate clinician-led category, review Medical Weight Loss. Specific campaign access still requires publisher approval.

The Topic

What Alli Is

Alli is the brand name for a 60mg over the counter dose of orlistat, a weight loss drug that works by blocking a portion of the fat a person eats from being absorbed. It was approved by the FDA in 2007 and remains the only FDA approved over the counter weight loss drug in the United States. A stronger, 120mg prescription version of orlistat is sold separately under the brand name Xenical.

Because Alli is an actual approved drug rather than a dietary supplement, and because it has a documented safety review in its history, people researching it tend to have specific, informed questions rather than casual curiosity.

Medical disclaimer. This page provides general background on Alli as a search topic for content and marketing purposes. It is not medical advice, does not diagnose or treat any condition, and should not replace guidance from a doctor or pharmacist.

Compliance

This Product's Compliance History

This is the single most important section on this page. Between 1999 and 2008, the FDA received 32 reports of serious liver injury in people taking orlistat, the active ingredient shared by Alli and Xenical. Of those, 27 involved hospitalization and six resulted in liver failure. Most of these cases were linked to Xenical or occurred outside the United States, and only a small number were specifically associated with Alli. The FDA opened a formal safety review of orlistat in 2009 and completed it in May 2010. The agency did not establish a confirmed cause and effect relationship between orlistat and liver injury. Alli was never recalled and remained available throughout the review. As a result, GSK updated the Alli product label to add a warning telling users to stop use and consult a doctor if they develop itching, yellow eyes or skin, dark urine or loss of appetite.

2007 FDA approves Alli, 60mg orlistat, as the only over the counter weight loss drug.

2009 FDA opens a formal safety review of orlistat after adverse event reports involving liver injury.

May 2010 FDA completes the review with no confirmed cause and effect link. GSK adds a liver injury warning to the Alli label. Alli remains on the market.

Known side effects Orlistat's approved labeling separately discloses common gastrointestinal side effects such as oily spotting and fecal urgency, related to its fat blocking mechanism.

Given this history, do the following when writing content built from this page.

Do not omit or minimize the FDA safety review when discussing the brand
Do not claim the review confirmed or ruled out a liver injury risk, since the FDA did not establish a cause and effect relationship either way
Do not imply the product carries no risk, and do not overstate the risk either
Never make a specific weight loss outcome or timeframe claim
Reference the known gastrointestinal side effects accurately if discussing user experience, rather than omitting them

Search Behaviour

Why Someone May Be Researching This Program

Search interest around Alli tends to fall into a few recurring patterns, which is useful context when planning content for this affiliate program.

Comparing to prescription options

People trying to understand how Alli differs from the prescription strength Xenical before deciding which to discuss with a doctor.

Side effect research

Because the gastrointestinal side effects are widely discussed, many searchers want to understand what to expect before starting.

Safety history questions

Readers who have heard about the liver injury review and want to understand what actually happened and where things stand.

Comparing to supplements

People weighing an FDA approved drug option against general dietary supplement categories.

Who You're Reaching

Relevant Audience for This Program

Content built around this program tends to reach an informed, research oriented audience, since Alli is a regulated drug with its own labeling and history rather than an unregulated supplement.

Typical audience traits

Adults specifically interested in an FDA approved, drug category option
Readers comparing Alli against prescription orlistat or general supplements
An audience researching known side effects before starting
Readers who want accurate information about the product's safety history

What this audience is wary of

Content that ignores or downplays the FDA safety review
Overstated safety claims that go beyond what the FDA actually found
Content that omits known gastrointestinal side effects
Content that doesn't distinguish general information from medical advice

Program status reviewed October 15, 2026

Current Program Status and Terms

Commission rates, attribution windows, approved countries, traffic permissions, reversals and payout conditions belong to the specific approved program. This article does not publish an unverified rate or transfer an older offer's terms to a different product.

Current product affiliate directory · Private telehealth directory · Historical program archive

Publisher next steps

How to Evaluate the Current Options

Open the current program page and identify the exact product or clinical-service category.
Use its designated signup route. Consumer product affiliates use the relevant product or network portal; private telehealth publishers apply for review.
Confirm the payable event, current commission, attribution, reversals, eligible markets and permitted traffic before launching.
Update existing links and creative to the approved current campaign, and disclose the affiliate relationship.

A private medical weight-loss category is a separate opportunity, not proof of an authorized Alli affiliate campaign.

Review current programs

Content Strategy

Content and Marketing Opportunities

Because Alli is an FDA regulated drug with a documented history, content that is accurate and transparent tends to build far more trust than promotional material that oversimplifies.

General educational content explaining how orlistat works as a fat blocker
Honest comparisons between Alli, prescription orlistat and general supplement categories
Accurate discussion of known gastrointestinal side effects
Factual context about the FDA safety review, without overstating or understating what was found
Content that clearly signals when a reader should consult a doctor or pharmacist rather than rely on an article alone

Compliance

Compliance Notes for This Category

This is a regulated drug with a real safety review in its history. Accurate, balanced information is the compliant approach, not silence and not alarm.

Health and wellness affiliate content generally carries more advertising restrictions than other categories, and OTC drug products can carry additional restrictions distinct from supplement products.

Confirm program authorization and trademark usage terms before publishing any branded content
Do not omit or minimize the FDA safety review history
Do not claim the review confirmed or ruled out a specific liver injury risk
Do not state or imply specific weight loss outcomes or timeframes
Do not present the content as medical advice
Disclose the affiliate relationship clearly on every piece of content
Confirm the permitted traffic sources and any region specific advertising rules before promoting
Encourage readers to consult a doctor or pharmacist before starting any weight loss drug

Choose a verified current route

Review Current Programs Before Promoting

Check the linked current product directory rather than treating this older article as a live offer listing.

View Current Product Programs

Programme FAQ

Frequently Asked Questions

Is this alli affiliate offer currently available?

This page covers an older Alli affiliate-program topic. A current campaign under that exact name has not been verified in the current public product directory. Do not use an earlier launch announcement, payout, trial or geographic claim as current offer terms. A private medical weight-loss category is a separate opportunity, not proof of an authorized Alli affiliate campaign. For a separate clinician-led category, review Medical Weight Loss . Specific campaign access still requires publisher approval.

What commission or cookie window applies?

No unverified percentage or attribution window is stated here. Use the current approved terms for the exact offer and account; do not reuse an older rate or assume every program has the same conditions.

Where should publishers go next?

Use the linked current product program pages for consumer offers. For clinician-led programs, apply through MarketHealth Telehealth Publishers and wait for approval and an approved campaign brief.

Was Alli linked to liver damage?

The FDA reviewed reports of serious liver injury involving orlistat, the ingredient in Alli, between 1999 and 2008, and most of the cases were linked to the prescription version Xenical or occurred outside the United States. The FDA completed its review in 2010 without confirming a cause and effect relationship, and Alli was never recalled.

Is Alli the same as Xenical?

They share the same active ingredient, orlistat. Alli is the 60mg over the counter version made by GSK, and Xenical is the 120mg prescription version made by Roche.

Can I say Alli has no side effects?

No. Orlistat's approved labeling discloses known gastrointestinal side effects related to its fat blocking mechanism, and content should reference these accurately rather than implying the product is side effect free.

Do I need special authorization to use the Alli name in my content?

Confirm with MarketHealth directly that this program is currently authorized, and understand any trademark or brand usage requirements before publishing content using the Alli name.

A Note on This Page

Program status reviewed October 15, 2026. This article retains topic and publishing guidance at its original URL. Its historical wording does not confirm current offer availability, a commission rate, a clinical benefit or permission to promote. Use the current program page and approved terms for each campaign.